Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd rose 2.83% today to trade at Rs 1733.95. The BSE Healthcare index is up 1.26% to quote at 42121.45. The index is up 4.26 % over last one month. Among the other constituents of the index, ERIS Lifesciences Ltd increased 2.7% and Aurobindo Pharma Ltd added 2.67% on the day. The BSE Healthcare index went up 20.02 % over last one year compared to the 13.3% surge in benchmark SENSEX. Sun Pharmaceutical Industries Ltd has added 2.75% over last one month compared to 4.26% gain in BSE Healthcare index and 9.71% rise in the SENSEX. On the BSE, 37402 shares were traded in the counter so far compared with average daily volumes of 58835 shares in the past one month. The stock hit a record high of Rs 1960.2 on 30 Sep 2024. The stock hit a 52-week low of Rs 1376.75 on 04 Jun 2024.Powered by Capital Market - Live

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1692.5, down 3% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 3.3% on the day, quoting at 24799.55. The Sensex is at 82017.47, up 3.23%.Sun Pharmaceutical Industries Ltd has eased around 0.73% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 0.77% in last one month and is currently quoting at 21071.75, up 0.01% on the day. The volume in the stock stood at 73.88 lakh shares today, compared to the daily average of 20.31 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 1693.4, down 3.24% on the day. Sun Pharmaceutical Industries Ltd jumped 10.98% in last one year as compared to a 12.19% rally in NIFTY and a 11.27% spurt in the Nifty Pharma index.The PE of the stock is 132.89 based on TTM earnings ending December 24.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd fell 5.32% today to trade at Rs 1652.1. The BSE Healthcare index is down 0.15% to quote at 41162.29. The index is up 1.89 % over last one month. Among the other constituents of the index, Suven Pharmaceuticals Ltd decreased 2.05% and Lupin Ltd lost 1.8% on the day. The BSE Healthcare index went up 18.64 % over last one year compared to the 11.79% surge in benchmark SENSEX. Sun Pharmaceutical Industries Ltd has lost 2.1% over last one month compared to 1.89% gain in BSE Healthcare index and 8.08% rise in the SENSEX. On the BSE, 37794 shares were traded in the counter so far compared with average daily volumes of 37750 shares in the past one month. The stock hit a record high of Rs 1960.2 on 30 Sep 2024. The stock hit a 52-week low of Rs 1376.75 on 04 Jun 2024.Powered by Capital Market - Live

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI), highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis. MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The two publications offer complementary insights into MM-II's clinical efficacy and mechanism of action, underscoring its potential therapeutic value. The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which enrolled 397 patients across the US, Europe and Asia. Findings demonstrate that a single injection of MM-II provided clinically meaningful pain relief through 26 weeks, with a favorable safety and tolerability profile. The second publication, titled 'Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,' details MM-II's unique mechanism of action. The research shows that MM-II forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration. The authors suggest that the results of the clinical trial may be mediated through the coating of the cartilage surfaces, though additional mechanisms may contribute to the long term pain reduction seen in Phase 2b study. 'The data from these publications show that MM-II has the potential to provide durable pain relief for patients,' said Prof. Thomas J Schnitzer, MD, PhD, a rheumatologist and professor of Medicine at Northwestern University and lead author of the clinical trial manuscript. 'With limited treatment options, lack of novel treatment approaches, and concerns around opioid use, MM-II may offer a promising alternative to hyaluronic acid and steroid treatments.' Powered by Capital Market - Live

Sun Pharmaceutical Industries announced that on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the Company's appeal of the U.S. District Court for the District of New Jersey's decision that previously granted a preliminary injunction delaying the Company's launch of LEQSELVI' (deuruxolitinib) in the United States. Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately. While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect. The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI'. The Company will disclose LEQSELVI' launch plans in due course of time.Powered by Capital Market - Live

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosive esophagitis of all grades. FEXUCLUE, containing Fexuprazan, is primarily used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and erosive esophagitis. It is also being studied for the prevention of NSAID-induced peptic ulcers and gastritis. Sun Pharma has obtained the rights from Daewoong Pharmaceutical, a South Korean biopharmaceutical company, to manufacture and commercialize FEXUCLUE in India. As part of the agreement, Daewoong will receive upfront and milestone payments, as well as royalties. Kirti Ganorkar, CEO of India Business, Sun Pharma, said, 'Erosive esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life. Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24. Shares of Sun Pharmaceuticals Industries fell 3.47% to Rs 1,650 on the BSE.Powered by Capital Market - Live

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name 'FEXUCLUE''. FEXUCLUE', a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades. Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE'(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.Powered by Capital Market - Live

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million. Powered by Capital Market - Live

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24Powered by Capital Market - Live